Company / R&D Expense
Disc Medicine, Inc. R&D Expense History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$170.6M
FY2025
5-year range
$25.2M / $170.6M
FY2021-FY2025
Trend
+76.5%
vs FY2024
Sector context
#93 of 210
Health Care
What the data says
At $171M, Disc Medicine, Inc.'s r&d expense ranks #93 of 210 in the Health Care sector. R&D Expense has increased for 4 consecutive years, from $25M in FY2021 to $171M in FY2025.
Based on SEC 10-K filings.
$171M in FY2025 with a 5-year CAGR of +43.4%.
Improved from $69M to $171M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +72.2%
- 5-Year CAGR
- +43.4%
- 10-Year CAGR
- -
Sector benchmark
#93 of 210 in Health CareTop 44% of 210This company $170.6M Sector average $644.0M
▼
-73.5% below sector average
Key checks
Key Insights
- Disc Medicine, Inc.'s r&d expense has grown for 4 consecutive years.
- 5-year CAGR of +43.4%, indicating consistent growth.
- In FY2025, r&d expense increased 76.5% year-over-year.
- Ranks #93 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 4.41 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $170.6M | +76.5% |
| FY2024 | $96.7M | +39.6% |
| FY2023 | $69.3M | +107.1% |
| FY2022 | $33.4M | +32.8% |
| FY2021 | $25.2M | -10.6% |
| FY2020 | $28.2M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026